On Thursday, Shares of Cognizant Technology Solutions Corp (NASDAQ:CTSH), lost -2.56% to $ 60.53.
Cognizant, offered an update on the status of its relationship with Health Net, Inc. (HNT) and reaffirmed its 2015 guidance following the declarement that Health Net has reached a contract to be attained by Centene Corporation (CNC).
“Recently’s declarement by Health Net and Centene is yet another example of how the healthcare landscape is rapidly changing, with increasing focus on medical costs, consumerization and a changing regulatory environment driving consolidation in addition to an ongoing search for solutions that fundamentally change the business model and economics of healthcare administration,” said Gordon Coburn, President, Cognizant. “As we congratulate Health Net and Centene recently, we look forward to ongoing to partner with them to support their technology and operations requirements.”
Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other.
Shares of PDL BioPharma Inc (NASDAQ:PDLI), declined -4.37% to $6.13, during its last trading session.
PDL BioPharma Inc, declared that it has reached a credit agreement with CareView Communications, Inc. (CRVW) whereby PDL will provide CareView with up to $40 million of secured debt financing. CareView is an information technology provider to the healthcare industry focused on patient care monitoring.
Under the credit agreement, PDL will provide CareView with up to $40 million of debt financing in two tranches of $20 million, based upon the achievement of specified milestones. Each tranche has a five year maturity. PDL will receive interest on the principal amount outstanding and has a security interest in substantially all of CareView’s assets. As part of the transaction, PDL received a warrant to purchase about 4.4 million shares of common stock of CareView at an exercise price of $0.45 per share.
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.
Finally, Bank Of The Ozarks Inc (NASDAQ:OZRK), ended its last trade with -1.74% loss, and close at $ 45.25.
Bank of the Ozarks, declared its Board of Directors has approved a regular quarterly cash dividend of $0.14 per common share payable July 24, 2015 to shareholders of record as of July 17, 2015. The dividend of $0.14 per common share represents an enhance of $0.005 per common share, or 3.7%, over the dividend paid in the previous quarter. The Company has raised its quarterly cash dividend in each of the last twenty quarters.
Bank of the Ozarks, Inc. is a bank holding company with $8.3 billion in total assets as of March 31, 2015 and trades on the NASDAQ Global Select Market under the symbol “OZRK.” The Company owns a state-chartered partner bank that conducts banking operations through 165 offices in Arkansas, Georgia, Texas, North Carolina, Florida, Alabama, South Carolina, New York and California. The Company may be contacted at (501) 978-2265 or P. O. Box 8811, Little Rock, Arkansas 72231-8811. The Company’s website is: www.bankozarks.com.
Bank of the Ozarks, Inc. operates as the bank holding company for Bank of the Ozarks that provides a range of retail and commercial banking services. The company accepts various deposits products, such as checking, savings, money market, time deposit, and individual retirement accounts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
